Piperacillin (PIPC) has excellent antibacterial activities against
Streptococcus pneumoniae, including penicillin-resistant
Streptococcus pneumoniae (PRSP), and
Haemophilus influenzae, including beta-lactamase-negative, ampicillin-resistant
Haemophilu.s influenzae (BLNAR). To demonstrate this clinically, we evaluated the clinical efficacy of PIPC on pneumonia and secondary infection with chronic respiratory disease in which
S. pneumoniae or
H. influenzae was considered a prophlogistic bacteria.
We found that the clinical efficacy ratio was 98.4% in all patients, and disappearance of
S. pneumoniae and
H. influenzae was 92.9% and 95.8%, sufficiently fulfilling the intended purpose. Bacteriological efficacy was 96.9% in monomicrobial infection (
S. pneumoniae: 100%,
H. influenzae: 93.8%) and 84.2% in polymicrobial infection. Monomicrobial and polymicrobial infections became negative in 92.2%. When a patient was treated based on infection with
S. pneumoniae or
H. influctizae, even in mixed infection, sufficient clinical effect was obtained in those with or without mixed infection.
The minimum inhibitory concentration (MIC) of PIPC for
S. pneumoniae and
H. influenzae isolated in this study was as follows: for
S. pneumoniae, the range of MIC was ≤0.06-4μg/mL and MIC
90 was 4μg/mL; and for
H. influenzae, the range of MIC was 0.06-8μg/mL and MIC
90 was 0.25μg/mL. The antibacterial activity against penicillin-intermediate
S. pneumoniae (PISP), PRSP, and BLNAR was 4 μg/mL of MIC
90 for PISP+PRSP and 0.25μg/mL of MIC
90 for BLNAR.
PIPC is thus clinically effective against patients with pneumonia and (with) secondary infection in chronic respiratory disease by
S. pneumoniae including PISP and PRSP, and
H. influenzae including BLNAR.
S. pneumoniae and
H. influenzae are highly probable prophlogistic bacteria of community-acquired pneumonia and secondary infection in chronic respiratory disease. In view of this, PIPC should prove to be an appropriate anti bacterial drug for empiric therapy for patients with community-acquired pneumonia and secondary infection in chronic respiratory disease.
View full abstract